MedDataX Logo

Comparative Microarray Analysis in Primary Cutaneous Malignant Melanoma

NCT ID: NCT01482260

Last Updated: 2012-11-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

21 participants

Study Classification

OBSERVATIONAL

Study Start Date

2011-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Perturbations in microRNA (miRNA) expression profiles has been reported for cutaneous malignant melanoma (CMM). This study will be an exploratory analysis by miRNA expression profiling using microarrays.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Perturbations in microRNA (miRNA) expression profiles has been reported for cutaneous malignant melanoma (CMM). With regards to a rapidly growing number of newly discovered miRNA sequences, the availability of up-to-date miRNA expression profiles for primary cutaneous malignant melanoma (PCMM), cutaneous malignant melanoma metastases (CMMM) and benign melanocytic naevi (BMN) is limited. Patients with PCMM, CMMM and BMN are included in the study to perform an exploratory analysis by miRNA expression profiling using microarrays. Expression levels of miRNA candidates will be validated by TaqMan real-time quantitative polymerase chain reaction (RT-PCR).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cutaneous Malignant Melanoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Primary Cutaneous Malignant Melanoma

Biopsy

Intervention Type PROCEDURE

Biopsy

Cutaneous Malignant Melanoma Metastases

Biopsy

Intervention Type PROCEDURE

Biopsy

Benign Melanocytic Nevi

Biopsy

Intervention Type PROCEDURE

Biopsy

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Biopsy

Biopsy

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Primary Cutaneous Malignant Melanoma
* Cutaneous Malignant Melanoma Metastases
* Benign Melanocytic Naevi

Exclusion Criteria

\- Other Skin Cancer than Primary Cutaneous Malignant Melanoma
Minimum Eligible Age

1 Year

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Ruhr University of Bochum

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Michael Sand

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Falk G Bechara, PD Dr.

Role: STUDY_DIRECTOR

Department of Dermatology, Venereology and Allergology, Ruhr-University Bochum

Peter Altmeyer, Prof. Dr.

Role: STUDY_CHAIR

Department of Dermatology, Venereology and Allergology, Ruhr-University Bochum

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Department of Dermatology, Venereology and Allergology, Ruhr-University Bochum

Bochum, North Rhine-Westphalia, Germany

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Germany

References

Explore related publications, articles, or registry entries linked to this study.

Sand M, Skrygan M, Sand D, Georgas D, Gambichler T, Hahn SA, Altmeyer P, Bechara FG. Comparative microarray analysis of microRNA expression profiles in primary cutaneous malignant melanoma, cutaneous malignant melanoma metastases, and benign melanocytic nevi. Cell Tissue Res. 2013 Jan;351(1):85-98. doi: 10.1007/s00441-012-1514-5. Epub 2012 Oct 31.

Reference Type RESULT
PMID: 23111773 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

microRNA5

Identifier Type: -

Identifier Source: org_study_id